MARKET

ICPT

ICPT

Intercept
NASDAQ

Real-time Quotes | Nasdaq Last Sale

65.07
-2.63
-3.88%
After Hours: 65.07 0 0.00% 16:56 03/27 EDT
OPEN
64.93
PREV CLOSE
67.70
HIGH
67.64
LOW
62.00
VOLUME
500.23K
TURNOVER
--
52 WEEK HIGH
125.00
52 WEEK LOW
47.57
MARKET CAP
2.14B
P/E (TTM)
-5.9696
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ICPT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 21 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ICPT stock price target is 151.90 with a high estimate of 257.00 and a low estimate of 89.00.

EPS

ICPT News

More
  • Hedge Funds Have Never Been This Bullish On Intercept Pharmaceuticals Inc (ICPT)
  • Insider Monkey · 13h ago
  • Drug makers on shaky ground as clinical trials are postponed and drug launches delayed amid pandemic
  • MarketWatch · 1d ago
  • After Crashing 33% In March, This Biotech Just Popped Here's Why
  • Investor's Business Daily · 2d ago
  • Ad Com postponed for Intercept's obeticholic acid; shares down 2% premarket
  • seekingalpha · 2d ago

Industry

Biotechnology & Medical Research
-2.44%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About ICPT

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.
More

Webull offers kinds of Intercept Pharmaceuticals Inc stock information, including NASDAQ:ICPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICPT stock news, and many more online research tools to help you make informed decisions.